Description

Madrigal Pharmaceuticals’ 50,000-Patient Breakthrough: Is Rezdiffra Just Getting Started?

Madrigal Pharmaceuticals reported strong growth in its second quarter of 2026, driven primarily by its liver-directed once-daily oral medication, Rezdiffra, approved for the treatment of Metabolic dysfunction-associated steatohepatitis (MASH). Net sales of Rezdiffra reached $364 million, up 71% year-over-year, with more than 49,000 active patients on therapy at quarter-end—a figure that more than doubled compared to the prior year. This patient growth continued into the third quarter, surpassing 50,000 patients early in July 2026. The company emphasized expanding prescriber depth among hepatologists and gastroenterologists as key drivers of growth, with recent efforts targeting endocrinologists still in early stages. Despite this, Madrigal expects stable growth in line with consensus for the remainder of the year. The U.S. MASH market has grown by nearly 50% over two years, driven by increased disease awareness, diagnoses, and specialist referrals, yet penetration remains low at approximately 10% of diagnosed patients, indicating considerable room for expansion.